FDA has announced that labeling for rosiglitazone (Avandia) has been changed to include information on cardiovascular risks (including death) connected with use of this agent.
FDA has announced that labeling for rosiglitazone (Avandia, GlaxoSmithKline) has been changed to include information on cardiovascular risks (including death) connected with use of this agent. In addition, labeling has been revised to state that rosiglitazone and medications that contain rosiglitazone should be used by patients already being treated with these agents, or by patients whose serum glucose levels cannot be controlled with other antidiabetic medications and who, after consulting with their healthcare providers, do not wish to use pioglitazone-containing medications (Actos, Actoplus Met, Actoplus Met XR, or Duetact).
Rosiglitazone is also sold as a combination product under the brand name Avandamet (containing rosiglitazone and metformin) and under the brand name Avandaryl (containing rosiglitazone and glimepiride).
In late September 2010, FDA announced that it would significantly restrict the use of medications containing rosiglitazone to patients with type 2 diabetes who cannot control their serum glucose levels with other medications. These new restrictions came about in response to data that suggested an elevated risk of myocardial infarction in patients treated with rosiglitazone.
The Risk Evaluation and Mitigation Strategy (REMS) that will restrict the availability of medications containing rosiglitazone has not yet been approved or formally implemented. FDA expects to approve the REMS by spring 2011 and expects the manufacturer to complete implementation 6 months thereafter.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
Assessing Financial Impacts of Pharmacist-Led Interventions in Pediatric Ambulatory Care
December 5th 2023According to a poster abstract presented at the ASHP Midyear Clinical Meeting & Exhibition, specialty pharmacy services were used for a variety of conditions that have been reported in adult populations.